JPWO2019152767A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019152767A5 JPWO2019152767A5 JP2020540738A JP2020540738A JPWO2019152767A5 JP WO2019152767 A5 JPWO2019152767 A5 JP WO2019152767A5 JP 2020540738 A JP2020540738 A JP 2020540738A JP 2020540738 A JP2020540738 A JP 2020540738A JP WO2019152767 A5 JPWO2019152767 A5 JP WO2019152767A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- construct
- constructs
- immune
- living
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002865 immune cell Anatomy 0.000 claims 19
- 210000004881 tumor cells Anatomy 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 12
- 210000004027 cells Anatomy 0.000 claims 9
- 238000000338 in vitro Methods 0.000 claims 9
- 210000002220 Organoids Anatomy 0.000 claims 8
- 230000000259 anti-tumor Effects 0.000 claims 4
- 210000001185 Bone Marrow Anatomy 0.000 claims 2
- 210000000987 Immune System Anatomy 0.000 claims 2
- 210000000265 Leukocytes Anatomy 0.000 claims 2
- 210000002751 Lymph Anatomy 0.000 claims 2
- 210000001165 Lymph Nodes Anatomy 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 230000002001 anti-metastasis Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 230000001809 detectable Effects 0.000 claims 1
- 230000001747 exhibiting Effects 0.000 claims 1
- 230000003328 fibroblastic Effects 0.000 claims 1
- 230000003325 follicular Effects 0.000 claims 1
- 239000001963 growth media Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 239000002609 media Substances 0.000 claims 1
- 230000001902 propagating Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Claims (20)
生きた腫瘍細胞および少なくとも１つのタイプの生きた免疫細胞を含む、
構築物。 In vitro cell construct,
Containing live tumor cells and at least one type of live immune cell,
Constructs.
前記の生きた腫瘍細胞は、対象内の腫瘍から集められ、および／または、得られる、
構築物。 The structure of claim 1
The living tumor cells are collected and / or obtained from a tumor in the subject.
Constructs.
前記の少なくとも１つのタイプの生きた免疫細胞は、対象内のリンパ節、骨髄、および／または末梢血から集められ、および／または、得られる、
構築物。 The structure of claim 1
The at least one type of live immune cell described above is collected and / or obtained from lymph nodes, bone marrow, and / or peripheral blood within the subject.
Constructs.
前記の生きた腫瘍細胞および前記の少なくとも１つのタイプの生きた免疫細胞は、同一対象から集められ、および／または、得られる、
構築物。 The structure of claim 1
The living tumor cells and at least one type of living immune cells described above are collected and / or obtained from the same subject.
Constructs.
前記の少なくとも１つのタイプの生きた免疫細胞は、濾胞樹状リンパ細胞、線維芽細網リンパ細胞、白血球、Ｂ細胞、Ｔ細胞、任意の骨髄細胞、および／または任意のリンパ系起源細胞である、
構築物。 The structure of claim 1
The at least one type of living immune cell described above is follicular dendritic lymph cells, fibroblastic reticular lymph cells, leukocytes, B cells, T cells, any bone marrow cells, and / or any lymphoid origin cells. ,
Constructs.
白血球をさらに含む、
構築物。 The structure of claim 1
Contains more white blood cells,
Constructs.
前記の生きた腫瘍細胞および前記の少なくとも１つのタイプの生きた免疫細胞は、約１：１～約１００：１（腫瘍細胞：免疫細胞）の比で前記構築物内に存在する、
構築物。 The structure of claim 1
The living tumor cells and the at least one type of living immune cells are present in the construct in a ratio of about 1: 1 to about 100: 1 (tumor cells: immune cells).
Constructs.
良性細胞をさらに含む、
構築物。 The structure of claim 1
Including more benign cells,
Constructs.
前記の腫瘍細胞および／または前記の少なくとも１つのタイプの生きた免疫細胞は、検出可能な化合物を含む、
構築物。 The structure of claim 1
The tumor cells and / or at least one type of live immune cells described above contain detectable compounds.
Constructs.
前記構築物は、少なくとも１週間、培地中で培養される、
構築物。 The structure of claim 1
The construct is cultured in medium for at least 1 week.
Constructs.
前記の腫瘍細胞、前記の少なくとも１つのタイプの生きた免疫細胞、および／または前記の良性細胞は、少なくとも５０％の生着率を有する方法を用いて調製される、
構築物。 The structure of claim 1
The tumor cells, the at least one type of live immune cells, and / or the benign cells are prepared using a method having an engraftment rate of at least 50%.
Constructs.
前記構築物は、培養の２週において、前記構築物内の細胞平均数に基づいて少なくとも７５％の生きた細胞を含む、
構築物。 The structure of claim 1
The construct comprises at least 75% of live cells based on the average number of cells in the construct at 2 weeks of culture.
Constructs.
ヒドロゲルをさらに含む、
構築物。 The structure of claim 1
Including more hydrogel,
Constructs.
前記構築物は、約１００万～約５００万、１０００万、２５００万、５０００万、７０００万、または１億個の細胞の範囲での細胞合計数を有する、
構築物。 The structure of claim 1
The construct has a total cell number in the range of about 1 million to about 5 million, 10 million, 25 million, 50 million, 70 million, or 100 million cells.
Constructs.
複数の生きた免疫細胞を含む、
構築物。 In vitro cell construct,
Contains multiple living immune cells,
Constructs.
前記の複数の生きた免疫細胞は、対象のリンパ節、末梢血、および／または骨髄から集められ、および／または、得られる、
構築物。 The structure of claim 15 .
The plurality of living immune cells described above are collected and / or obtained from the lymph nodes, peripheral blood, and / or bone marrow of interest.
Constructs.
請求項１５の構築物を提供するステップ；
前記の目的化合物を前記構築物にインビトロで接触させるステップ；そして、
前記の目的化合物を前記構築物にインビトロで接触させるステップに応じて、前記構築物の免疫応答を判定するステップ、
を含む、
方法。 A method of screening the compound of interest for immune activity in vitro and / or a method of regulating the immune system.
The step of providing the construct of claim 15 ;
The step of bringing the compound of interest into contact with the construct in vitro;
A step of determining the immune response of the construct in response to the step of in vitro contacting the construct with the compound of interest.
including,
Method.
請求項１の構築物を提供するステップ；
前記の目的化合物を前記構築物にインビトロで接触させるステップ；そして、
前記の目的化合物を前記構築物にインビトロで接触させるステップに応じて、生きた腫瘍細胞の増殖を判定し、前記の目的化合物の抗腫瘍活性を示すステップ
を含む、
方法。 A method of screening the compound of interest for antitumor activity in vitro.
The step of providing the construct of claim 1;
The step of bringing the compound of interest into contact with the construct in vitro;
The step comprises contacting the construct with the target compound in vitro to determine the growth of living tumor cells and exhibiting the antitumor activity of the target compound .
Method.
請求項１５の構築物および生きた腫瘍細胞オルガノイドを含むデバイスを提供するステップ；
前記構築物および前記の生きた腫瘍細胞オルガノイドを増殖培地と接触させるステップ；
目的化合物を前記構築物および／または前記の生きた腫瘍細胞オルガノイドに接触させるステップ；および
前記の目的化合物を前記構築物および／または前記の生きた腫瘍細胞オルガノイドに接触させるステップに応じて、前記の生きた腫瘍細胞の増殖を判定するステップ、ここで、前記の生きた腫瘍細胞の増殖における低減は、前記の目的化合物の抗腫瘍活性を示す、および／または、前記免疫細胞オルガノイドおよび／または前記の生きた腫瘍細胞オルガノイドの免疫応答を判定するステップ
を含む、
方法。 A method of screening a compound of interest for immune activity in vitro, a method of regulating the immune system, anti-metastatic activity, and / or antitumor activity.
A step of providing a device comprising the construct of claim 15 and a living tumor cell organoid;
The step of contacting the construct and the live tumor cell organoid with the growth medium;
Depending on the step of contacting the target compound with the construct and / or the live tumor cell organoid; and the step of contacting the target compound with the construct and / or the live tumor cell organoid, said live. The step of determining the growth of tumor cells , wherein the reduction in the growth of the living tumor cells indicates the antitumor activity of the compound of interest and / or the immune cell organoid and / or the living. Including steps to determine the immune response of tumor cell organoids,
Method.
前記方法は、
免疫細胞を複数の生きた腫瘍細胞を含む生きた腫瘍細胞オルガノイドに接触させて、活性化された免疫細胞を提供するステップ；
前記の活性化された免疫細胞を前記の生きた腫瘍細胞オルガノイドから分離して、分離された活性化された免疫細胞を提供するステップ；および
前記の分離された活性化された免疫細胞を増殖させて、活性化された免疫細胞の集団を提供するステップ
を含む、
方法。
A method of activating immune cells with Exvivo,
The method is
The step of contacting immune cells with live tumor cell organoids, including multiple live tumor cells, to provide activated immune cells;
The step of separating the activated immune cells from the living tumor cell organoid to provide isolated activated immune cells; and propagating the isolated activated immune cells. Including the step of providing a population of activated immune cells,
Method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118838A JP2023139153A (en) | 2018-02-02 | 2023-07-21 | Organoids related to immunotherapy and methods of preparing and using the same |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625628P | 2018-02-02 | 2018-02-02 | |
| US62/625,628 | 2018-02-02 | ||
| PCT/US2019/016236 WO2019152767A1 (en) | 2018-02-02 | 2019-02-01 | Organoids related to immunotherapy and methods of preparing and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118838A Division JP2023139153A (en) | 2018-02-02 | 2023-07-21 | Organoids related to immunotherapy and methods of preparing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021511790A JP2021511790A (en) | 2021-05-13 |
| JPWO2019152767A5 true JPWO2019152767A5 (en) | 2022-01-21 |
Family
ID=67478724
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540738A Pending JP2021511790A (en) | 2018-02-02 | 2019-02-01 | Immunotherapy organoids and how to prepare and use them |
| JP2023118838A Pending JP2023139153A (en) | 2018-02-02 | 2023-07-21 | Organoids related to immunotherapy and methods of preparing and using the same |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118838A Pending JP2023139153A (en) | 2018-02-02 | 2023-07-21 | Organoids related to immunotherapy and methods of preparing and using the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200363402A1 (en) |
| EP (1) | EP3746785A4 (en) |
| JP (2) | JP2021511790A (en) |
| KR (1) | KR20200116944A (en) |
| AU (1) | AU2019215096A1 (en) |
| CA (1) | CA3089127A1 (en) |
| WO (1) | WO2019152767A1 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016331081B2 (en) | 2015-10-02 | 2021-04-29 | Wake Forest University Health Sciences | Methods and apparatus for modeling cancer metastasis in vitro |
| CA3039822A1 (en) | 2016-10-14 | 2018-04-19 | Wake Forest University Health Sciences | Compositions, cell constructs, and methods of making and using the same |
| WO2018081425A1 (en) | 2016-10-26 | 2018-05-03 | Wake Forest University Health Sciences | Hydrogen-bonding compounds, compositions comprising the same, and methods of preparing and using the same |
| US11629329B2 (en) | 2017-10-11 | 2023-04-18 | Wake Forest University Health Sciences | Bioink compositions and methods of preparing and using the same |
| US11213608B2 (en) | 2018-08-14 | 2022-01-04 | Wake Forest University Health Sciences | Compositions including gelatin nanoparticles and methods of use thereof |
| US11415571B2 (en) | 2019-12-05 | 2022-08-16 | Tempus Labs, Inc. | Large scale organoid analysis |
| US11561178B2 (en) | 2020-04-20 | 2023-01-24 | Tempus Labs, Inc. | Artificial fluorescent image systems and methods |
| JP2023550651A (en) * | 2020-11-24 | 2023-12-04 | デューク ユニバーシティ | Droplet organoid-based cancer immunology assays and methods of using them |
| US20240110155A1 (en) * | 2020-12-17 | 2024-04-04 | Genome Biologics Ug | A dual cardiac-blood model system for disease modelling and drug screening |
| WO2022154754A1 (en) * | 2021-01-15 | 2022-07-21 | Nanyang Technological University | Core-shell microspheres |
| EP4060552A1 (en) * | 2021-03-15 | 2022-09-21 | Universiteit Antwerpen | Label-free analysis of brightfield microscope images |
| WO2023043787A1 (en) * | 2021-09-15 | 2023-03-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of amplifying tumor-reactive immune populations using organoids |
| KR102527911B1 (en) * | 2022-08-02 | 2023-05-02 | 오가노이드사이언스 주식회사 | Use of regulatory t cell for drug screening |
| WO2023043278A1 (en) * | 2021-09-17 | 2023-03-23 | 오가노이드사이언스 주식회사 | Method for evaluating efficacy of anticancer agent or screening anticancer agent |
| KR102511632B1 (en) * | 2022-07-26 | 2023-03-20 | 오가노이드사이언스 주식회사 | Method for evaluating efficacy of anti-cancer agent using tumor microenvironment comprising cancer organoid and til |
| KR102511633B1 (en) * | 2022-08-09 | 2023-03-20 | 오가노이드사이언스 주식회사 | Method for evaluating efficacy of anti-cancer agent using mixture of m1 macrophage and m2 macrophage |
| KR102527906B1 (en) * | 2022-07-29 | 2023-05-02 | 오가노이드사이언스 주식회사 | Use of dendritic cell for evaluating drug efficacy |
| CN115521912A (en) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | Immune cell treatment method by co-culture of organoid and T cell and application |
| CN115537395A (en) * | 2021-11-04 | 2022-12-30 | 上海万何圆生物科技有限公司 | Treatment method for co-culture of liver cancer organoid and TILs (tumor necrosis factor-associated stem cells) and application thereof |
| CN115521898A (en) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | Immune cell treatment method for co-culture of liver cancer organs and NK cells and application |
| KR20230121232A (en) * | 2022-02-10 | 2023-08-18 | 가톨릭대학교 산학협력단 | Patient-derived meningioma organoids and method for preparing thereof |
| CN117511880B (en) * | 2024-01-08 | 2024-04-19 | 北京大橡科技有限公司 | Method for constructing in-vitro tumor in-situ model, culture medium and in-vitro application |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69725317T2 (en) * | 1996-04-03 | 2004-07-29 | The Rogosin Institute | IMPLANTABLE AGAROSE COLLAGEN BALLS CONTAINING CELLS THAT MAKE A DIFFUSIONABLE BIOLOGICAL PRODUCT AND THEIR USE |
| US6224912B1 (en) * | 1996-04-03 | 2001-05-01 | The Rogo Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| PL376471A1 (en) * | 2002-10-11 | 2005-12-27 | Novocell, Inc. | Implantation of encapsulated biological materials for treating diseases |
| US8298824B2 (en) * | 2004-04-28 | 2012-10-30 | Sanofi Pasteur Vaxdesign Corporation | Methods of evaluating a test agent in a diseased cell model |
| RU2577702C2 (en) * | 2010-02-11 | 2016-03-20 | Ф.Хоффманн-Ля Рош Аг | Nk-cell 3d-facs-analysis-adcc |
| CA2950353C (en) * | 2014-05-26 | 2022-11-01 | Universitatsspital Basel | In vitro culturing or expanding human or animal tissue |
| WO2016081554A1 (en) * | 2014-11-18 | 2016-05-26 | Neostem Oncology, Llc | Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use |
| AU2016331081B2 (en) * | 2015-10-02 | 2021-04-29 | Wake Forest University Health Sciences | Methods and apparatus for modeling cancer metastasis in vitro |
| GB2600648B (en) * | 2016-03-30 | 2022-08-10 | Emulate Inc | Devices, systems and methods for inhibiting invasion and metastases of cancer |
| JP7038353B2 (en) * | 2016-04-13 | 2022-03-18 | ヴィヴィア バイオテック，エス．エル | Exvivo BITE-activated T cells |
| JP7178264B2 (en) * | 2016-05-25 | 2022-11-25 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Compositions and methods for organoid production and disease modeling |
| WO2018013589A1 (en) * | 2016-07-12 | 2018-01-18 | Flagship Pioneering, Inc. | Methods and compositions for thymic transplantation |
| US11180735B2 (en) * | 2016-10-28 | 2021-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof |
-
2019
- 2019-02-01 US US16/966,406 patent/US20200363402A1/en active Pending
- 2019-02-01 AU AU2019215096A patent/AU2019215096A1/en active Pending
- 2019-02-01 WO PCT/US2019/016236 patent/WO2019152767A1/en unknown
- 2019-02-01 KR KR1020207023638A patent/KR20200116944A/en not_active Application Discontinuation
- 2019-02-01 CA CA3089127A patent/CA3089127A1/en active Pending
- 2019-02-01 EP EP19746913.3A patent/EP3746785A4/en active Pending
- 2019-02-01 JP JP2020540738A patent/JP2021511790A/en active Pending
-
2023
- 2023-07-21 JP JP2023118838A patent/JP2023139153A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019152767A5 (en) | ||
| Chen et al. | Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model | |
| Zaba et al. | Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells | |
| Moroso et al. | NK cells can generate from precursors in the adult human liver | |
| Egawa et al. | The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor | |
| Lutzner et al. | Different papillomaviruses as the causes of oral warts | |
| JP7097814B2 (en) | Genetic markers for engraftment of human ventricular progenitor cells | |
| CN109735574A (en) | A method of improving fetal hemoglobin expression | |
| Đokić et al. | Characterization and immunosuppressive properties of mesenchymal stem cells from periapical lesions | |
| CN1878860A (en) | Method of isolating and culturing mesenchymal stem cell derived from umbilical cord blood | |
| JP2023002579A (en) | Human innate lymphoid cell precursors: identification, characterization, applications | |
| Hu et al. | Single-cell analysis reveals the origins and intrahepatic development of liver-resident IFN-γ-producing γδ T cells | |
| Eberlein et al. | Aging promotes acquisition of naive-like CD8+ memory T cell traits and enhanced functionalities | |
| Coppari et al. | Fragmentation, re-attachment ability and growth rate of the Mediterranean black coral Antipathella subpinnata | |
| CN1878861B (en) | Method of isolating and culturing mesenchymal stem cell derived from cryopreserved umbilical cord blood | |
| Zimmer et al. | Mycoplasma-like organisms: occurrence with the larvae and adults of a marine bryozoan | |
| Alisjahbana et al. | CD5 surface expression marks intravascular human innate lymphoid cells that have a distinct ontogeny and migrate to the lung | |
| CN1606615A (en) | Method for expanding hematopoietic stem cells | |
| CN109913461A (en) | Tip of a root dental papilla stem cell excretion body piRNA biomarker and its screening application | |
| 日野明徳 et al. | Relationship between the temperature given at the time of fertilized egg formation and bisexual reproduction pattern in the deriving strain of the rotifer Brachionus plicatilis. | |
| CN113717928B (en) | Method for constructing 3D liver bud organoid based on framework nucleic acid material and application | |
| Vickery et al. | Morphogenesis and organogenesis in the regenerating planktotrophic larvae of asteroids and echinoids | |
| Korniotis et al. | GM-CSF-activated human dendritic cells promote type 1 T follicular helper cell polarization in a CD40-dependent manner | |
| Boury-Esnault et al. | Glycogen storage and transfer in primitive invertebrates: Demospongea and Actiniaria. In: Lévi, C. & Boury-Esnault, N.(eds) Biologie des Spongiaires. Sponge Biology. | |
| Burnett et al. | Growth and differentiation of Tabularía cells in a chemically defined physiological medium |